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Tissue engineered constructs (TECs) based on spheroids of bone marrow mesenchymal stromal
cells (BM‐MSCs) combined with calcium phosphate microparticles and enveloped in a platelet‐
rich plasma hydrogel showed that aggregation of MSCs improves their ectopic bone formation
potential. The stromal vascular fraction (SVF) and adipose‐derived MSCs (ASCs) have been recog-
nized as an interesting MSC source for bone tissue engineering, but their ectopic bone formation
is limited. We investigated whether aggregation of ASCs could similarly improve ectopic bone
formation by ASCs and SVF cells. The formation of aggregates with BM‐MSCs, ASCs and SVF
cells was carried out and gene expression was analysed for osteogenic, chondrogenic and
vasculogenic genes in vitro. Ectopic bone formation was evaluated after implantation of TECs in
immunodeficient mice with six conditions: TECs with ASCs, TECs with BM‐MSC, TECs with
SVF cells (with and without rhBMP2), no cells and no cells with rhBMP2. BM‐MSCs showed con-
sistent compact spheroid formation, ASCs to a lesser extent and SVF showed poor spheroid for-
mation. Aggregation of ASCs induced a significant upregulation of the expression of osteogenic
markers like alkaline phosphatase and collagen type I, as compared with un‐aggregated ASCs.
In vivo, ASC and SVF cells both generated ectopic bone in the absence of added morphogenetic
proteins. The highest incidence of bone formation was seen with BM‐MSCs (7/9) followed by
SVF + rhBMP2 (4/9) and no cells + rhBMP2 (2/9). Aggregation can improve ectopic bone tissue
formation by adipose‐derived cells, but is less efficient than rhBMP2. A combination of both fac-
tors should now be tested to investigate an additive effect.
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Bridging critical sized bone defects is one of the main current
challenges in orthopaedic and trauma surgery. These defects can result
from resection of bone tumours, trauma or infection and affect mainly
younger patients. The current gold standard for bridging these defects
is autologous grafting of bone from the iliac crest or proximal tibia. The
complications, donor site infection and pain, of these procedures are
well known and frequently mentioned as arguments for alternative
solutions. One is the use of bone graft substitutes with mesenchymal
stromal or stem cells (MSCs) derived from bone marrow combined
with biomaterials, and sometimes growth factors, to be delivered intotd. wileyonlinelibrarthe defect site. However, bone marrow is not the only source of MSCs.
Alternate sources of multipotent MSCs are, for instance, adipose
tissue, periosteum, synovial fluid, peripheral blood and muscle
(Sakaguchi, Sekiya, Yagishita, & Muneta, 2005; Zuk et al., 2002;
Zvaifler et al., 2000). MSCs from adipose tissue (ASCs) are typically
derived from the stromal vascular fraction (SVF) of adipose tissue by
monolayer expansion in vitro. SVF is a heterogeneous population of
endothelial cells, macrophages, erythrocytes, pericytes, lymphocytes
and pre‐adipocytes (Gimble, Grayson, Guilak, Lopez, & Vunjak‐
Novakovic, 2011) obtained by digestion of adipose tissue followed
by separation from the mature adipocytes by centrifugation (Gimble,
Katz, & Bunnell, 2007). Bone marrow MSCs (BM‐MSCs) and ASCsJ Tissue Eng Regen Med. 2018;12:e150–e158.y.com/journal/term
FENNEMA ET AL. e151are commonly used in skeletal tissue engineering in vitro and in vivo
(Gamie et al., 2012).
We have extensively used ceramic scaffolds in combination with
BM‐MSCs in two‐dimensional (Meijer, de Bruijn, Koole, & van
Blitterswijk, 2008; Siddappa et al., 2008). More recently, we developed
a three‐dimensional culture system to generate tissue engineered con-
structs (TECs) based on spheroids of MSCs with an average diameter
of 140 μm, mixed with porous calcium phosphate ceramic particles
of 53–63 μm in diameter and enveloped by a platelet‐rich plasma
hydrogel. This system demonstrated more bone formation than the
standard two‐dimensional approach (Chatterjea et al., 2013; Rivron
et al., 2012,). In general, three‐dimensional culturing techniques confer
a higher degree of clinical relevance to preclinical studies than two‐
dimensional. For example, primary rat hepatocytes showed positive
signalling for Connexin 32 again after aggregation (Bierwolf et al.,
2011) and Pannexin 1, a gap junction protein, plays a pivotal role in
aggregate assembly and, hence, in intercellular biomechanical
interactions that drive the progression of cancer (Bao, Lai, Naus, &
Morgan, 2012).
ASCs have also been used in three‐dimensional culture systems
aiming at skeletal tissue engineering. However, bone formation by
ASCs was only seen after preculturing (Güven et al., 2011) and/or
the addition of rhBMP2 (Shen et al., 2013). To increase the clinical
applicability, we aim to shorten in vitro culture times as much as possi-
ble. Furthermore, the incorporation of growth factors brings about
extensive clinical testing before it can be applied in patients, and has
only a few indications (e.g. spinal fusion).
Therefore, the aim of this study was to analyse the use of aggre-
gated SVF, ASCs or BM‐MSC for bone tissue engineering in the form
of TECs without the addition of morphogenetic growth factors. For
each of these cell sources, we compared the differences in differentia-
tion in vitro and bone formation in vivo.2 | MATERIALS AND METHODS
2.1 | Cell culture
Bone marrow aspirates (5–20 ml) were obtained from healthy donors
during hip replacement surgery with written informed consent and
MSCs were isolated as described previously (Siddappa, Licht, van
Blitterswijk, & de Boer, 2007). Basic mediumwas made up of α‐minimal
essential medium (α‐MEM; LifeTechnologies), 10% fetal bovine serum
(Cambrex), 0.2 mM ascorbic acid (Asap; Life Technologies), 2 mM
L‐glutamine (Life Technologies), 100 U/ml penicillin (Life Technolo-
gies) and 10 mg/ml streptomycin (Life Technologies). Proliferation
medium consisted of basic medium supplemented with 1 ng/ml basic
fibroblast growth factor (Instruchemie, the Netherlands). Induction
medium (for osteogenic differentiation studies and prior to in vivo
implantation) was composed of D‐MEM (Life Technologies) supple-
mented with 10−7 M dexamethasone (Sigma‐Aldrich, USA), 50 mg/ml
ascorbic acid (Life Technologies), 40 mg/ml proline (Sigma‐Aldrich),
100 mg/ml sodium pyruvate (Life Technologies), 50 mg/ml ITS Premix
(Becton‐Dickinson, USA). Mineralization medium consisted of basic
medium with 10−8 M dexamethasone (Sigma‐Aldrich) and 0.01 M β‐glycerol phosphate (Sigma‐Aldrich). Adipogenic mediumwas composed
of D‐MEM (LifeTechnologies), 100 U/ml penicillin +100mg/ml strepto-
mycin (Life Technologies), 10% fetal bovine serum (Cambrex), 0.2 mM
indomethacin (Sigma‐Aldrich), 0.5 mM IBMX (Sigma‐Aldrich), 10−6 M
dexamethasone (Sigma‐Aldrich) and 10 mg/ml insulin (human, Sigma‐
Aldrich). Cells were grown at 37°C in a humid atmosphere with 5%
CO2. Medium was refreshed every 3–4 days. Cells were grown to near
confluence in proliferation medium before their use in experiments.
Lipoaspirates, 10–100 ml, were obtained from donors during rou-
tine lipoaspirations of the inner and/or outer thighs after informed
consent from the patient and following protocol approval by the local
ethical committee. SVF cells were obtained after digestion of
lipoaspirates in 0.075% collagenase type 2 (Worthington Biochem
USA) for 45 min at 37°C on an orbital shaker (Scherberich, Galli,
Jaquiery, Farhadi, & Martin, 2007). SVF cells were allowed to adhere
to tissue culture plastic in proliferation medium and trypsinized when
reaching near confluence. These cells were ASCs. ASCs were derived
from the same donors as the SVF cells.
Spheroids were created using previously described methods
(Chatterjea et al., 2013). In short, 1.5 million cells were seeded in
microwells (400 μm diameter, 200 μm depth) on a patterned agarose
chip (surface area 3.8 cm2). After 24 h, spheroids were formed in most
cases. We fabricated the TECs as described previously (Chatterjea
et al., 2013). Briefly, 1.5 million cells in spheroids were combined with
calcium phosphate ceramic scaffolds and a platelet‐rich plasma gel and
these were cultured in basic or induction medium for 1 day prior to
implantation or 7 days in case of in vitro analysis. To compare TECs
prior to implantation, SVF‐, ASC‐ and BM‐MSC‐based TECs were
analysed by histology. Two BM‐MSC donors were used and one SVF
and one ASC donor was used. Both BM‐MSCs and ASCs were P1‐2 cells.2.2 | Differentiation experiments
The adipogenic differentiation protocol was as follows: human MSCs
were seeded at 10 000 cells/cm2 and grown in adipogenic medium
for 21 days. Medium was refreshed every 3–4 days and lipid formation
was visualized after 21 days by Oil Red O staining. In the mineraliza-
tion protocol, human MSCs were seeded at 5000/cm2 and grown in
mineralization medium inT25 culture flasks for 21–28 days until robust
mineralization was observed in the positive control. Mineralization was
visualized with Alizarin Red staining. Cells grown in basic medium plus
0.01 M β‐glycerol phosphate (Sigma) were used as the negative control.
SVFs could not be subjected to our two‐dimensional adipogenic and
mineralization assays as they could no longer be considered as SVFs
but as ASCs.2.3 | Gene expression analysis
TECs were rinsed with phosphate‐buffered saline (PBS), crushed man-
ually and lysed using Trizol (Invitrogen). After the addition of chloro-
form and phase separation by centrifugation, the aqueous phase was
aspirated and mixed with an equal volume of 75% ethanol. This RNA
containing mixture was processed for purification using an RNA isola-
tion kit (Machery‐Nagel Germany) according to the manufacturer's pro-
tocol. The RNA concentration was analysed by spectrophotometry using
TABLE 1 Summary of bone formation in vivo. All the conditions are
listed in the first column. When bone formation was observed this was
counted relative to the total number of mice. Bone marrow mesen-
chymal stromal cells (BM‐MSCs) showed the highest bone incidence,
followed by stromal vascular fraction (SVF) + rhBMP2 and no cells +
rhBMP2. When using other cell sources, bone formation can only be
achieved reliably by the addition of rhBMP2
Bone No bone
BM‐MSC 7/9 2/9
No cells ‐ 9/9
No cells + rhBMP2 2/9 7/9
SVF 1/9 8/9
SVF + rhBMP2 4/9 5/9
ASC 1/9 8/9
ASC, adipose‐derived mesenchymal stromal cells.
e152 FENNEMA ET AL.the Nanodrop 1000 (Isogen Life Science The Netherlands). cDNA was
synthesized using iScript (Bio‐rad USA). Quantitative polymerase chain
reaction (qPCR) results were obtained with a double‐stranded DNA‐
binding dye, SYBR Green (Invitrogen). Primers were acquired from Sigma
and sequences are shown in Table 1. Real‐time qPCR was performed
and gene expression was normalized to either glyceraldehyde‐3‐phos-
phate dehydrogenase or β2‐microglobulin. Relative gene expressions
were calculated using the ΔΔCt method.2.4 | Animal experiments
To assess the bone‐forming capacity of TECs we analysed ectopic
bone formation in immunodeficient mice. After an acclimatization
period of at least 7 days, mice were used for further studies. To allevi-
ate peri‐operative pain, mice were administered Temgesic s.c.
(Schering‐Plough BV USA). The surgeries were carried out under gen-
eral anaesthesia. Induction of anaesthesia consisted of 4% isoflurane,
followed by 2–2.5% isoflurane to maintain general anaesthesia. Four
equally spaced dorsal incision sites were disinfected with 70% ethanol.
A pocket was created by making a small skin incision (3 mm), followed
by spreading of the subcutaneous tissue with blunt scissors. One TEC
per pocket was implanted. The skin was closed with resorbing sutures
or staples. For each animal study, 10 immunodeficient male mice (Hsd‐
cpb: NMRI‐nu, Harlan) were used. For the implantations, the cells for
the ASC and SVF TECs originated from the same donors (donors
257, 262, 267). Only one BM‐MSC donor was used (D240) as refer-
ence. All ASCs and BM‐BMCs were P1 cells. Mice were fed ad libitum.
Of 10 mice, one mouse died from an infection. After 6 weeks of
implantation, mice were terminated with CO2. Samples were excised
directly after termination and stored in fixative. All animal experiments
were approved by the local animal welfare committee of either Utrecht
or Basel and performed by licensed personnel according to Dutch or
Swiss law.2.5 | Histological analysis
Upon explantation, samples were fixed in 4% paraformaldehyde. The
samples were dehydrated using either a graded series of ethanol, afterdecalcification in EDTA‐PBS solution for 5 days with daily renewal of
the solution (paraffin‐embedded samples), or a histological micro-
wave (Milestone Histoprocessor Italy) with methyl methacrylate
(MMA)‐embedded samples. MMA‐embedded samples were cut to
slides of 10–15 μm thickness using a diamond saw rotatory
microtome (Leica SP1600); 7 μm sections were generated from
paraffin‐embedded samples. MMA‐embedded samples were stained
with methylene blue and basic fuchsin. Paraffin‐embedded
samples were stained with haematoxylin/eosin or Mason‐trichrome.
In qualitative bone assessment, bone incidence per condition was
counted, as well as the maturity of the bone formed. Bone forma-
tion was assessed qualitatively.2.6 | Bone quantification and qualification
A minimum of three sections per sample were used for quantifica-
tion, equally spread across the sample. Slides from MMA‐embedded
samples were scanned using a Pathscan Enabler IV (Meyer Instru-
ments USA); the paraffin‐embedded samples were scanned using a
Hamamatsu Nanozoomer 2.0‐RS (Hamamatsu Japan). After digitaliza-
tion of the slides, the bone and scaffold area were quantified by
pseudo‐colouring of the respective tissue and counting pixels using
Adobe Photoshop CS5.2.7 | Statistical analyses
Statistical analyses were performed using IBM SPSS Statistics 22. Prior
to analyses, data were checked for normality. In the case of positively
skewed data, logarithmic transformation assured normality. When two
groups were compared, Student's t‐test for paired groups was used.
When more groups were compared, ANOVA with Bonferroni's correc-
tion for multiple comparisons was used. A p value <0.05 was consid-
ered significant.3 | RESULTS
3.1 | BM‐MSCs and ASCs both differentiate into
osteoblasts and adipocytes
To determine multipotency of the BM‐MSCs and ASCs used in the
present study they were cultured with mineralization and adipogenic
medium, respectively. Both BM‐MSCs and ASCs mineralized well in
mineralization medium, whereas no mineral was observed in the con-
trol condition. Similarly, comparable levels of adipogenic differentia-
tion were observed with both cell sources (Figure 1). As mentioned,
SVF could not be subjected to our two‐dimensional differentiation
assays, as they would become ASCs then.3.2 | Spheroid formation is cell source dependent
We previously observed more bone formation when aggregated BM‐
MSCs were used as the cell source compared with single cells. There-
fore, we analysed the capacity of ASCs and SVF cells for spheroid for-
mation. Cells were seeded in agarose moulds and after centrifugation
cells were left for 24 h in basic medium. Spheroid formation was
FIGURE 1 Adipose‐derived (ASCs) and bone marrow mesenchymal stromal cells (BM‐MSCs) show osteogenic and adipogenic differentiation.
ASCs and BM‐MSCs were differentiated into the osteogenic and adipogenic lineage. The upper row (a) shows ASCs, the bottom row BM‐
BMSCs (b). From left to right are images of controls, mineralization and adipogenesis. No mineralization is present in the control (basic) conditions.
Mineralization is visualized with Alizarin Red staining. The far right panels show intracellular fat droplets indicating that our cells successfully
differentiated into adipocytes. The mineralization was more intense in BM‐MSCs compared with ASCs. Adipogenic differentiation was the same as
in ASCs. Scale bars indicate 100 μm
FENNEMA ET AL. e153analysed by light microscopy. As observed previously, BM‐MSC spher-
oid formation occurred within 24 h (Figure 2, fourth row). ASCs also
formed spheroids, which appeared less compact, i.e. more translucent
than the BM‐MSC spheroids and not as ‘rounded off’ (Figure 2, third
and fourth rows). SVF did not reliably form spheroids. Three SVF
donors were used to illustrate the differences between donors. In
donor 262, cells were seeded as single cells in the wells (Figure 2, first
row) and, at best, there was only a poorly organized spheroid‐like
structure with SVF cells from donor 257 (Figure 2, second row).
Spheroids were then implanted in vivo with Biphasic calcium phosphate
(BCP) particles and an enveloping platelet‐rich plasma gel after 24 h of
exposure to induction medium.We analysed if cells were still in the form
of spheroids upon implantation. Of the three cell sources, compact
spheroids were only observed in BM‐MSC‐based TECS, whereas ASCs
and SVF cells were not organized in spheroids in the samples but rather
as single cells (data not shown). Hence, with this protocol, only BM‐
MSCs reliably retained a spheroid configuration before implantation.3.3 | BM‐MSC spheroids display a stronger
osteogenic profile than ASCs and SVF cells
To study the effect of aggregation on osteogenesis by ASCs and SVF
cells, TECs were exposed to either induction medium or basic medium
for 7 days. We thereafter determined the expression of osteogenic
[BMP2, alkaline phosphatase (ALP) and collagen type I (Col I)],
chondrogenic (Col II and Col X) and pro‐angiogenic Vascular endothelial
growth factor (VEGF) genes (Figure 3). With regards to the osteogenic
profile, BMP2 was only increased 1.3‐fold in BM‐MSCs and decreased
0.7‐fold in ASCs. Col I increased in both BM‐MSCs and ASCs 1.4‐fold
and 2.9‐fold, respectively, the latter being a significant increase. ALP
expression also increased in both cell types upon exposure to induction
medium compared with basic medium with 46‐fold in BM‐MSCs and8‐fold in ASCs, both significant increases. The expression of Col II simi-
larly increased in both cell types, by 2.4‐fold and 2.5‐fold in BM‐MSC
and ASC, respectively, upon exposure to the induction medium. The
expression of Col X increased 4.7‐fold in BM‐MSCs but was undetect-
able in ASCs. VEGF expression decreased in both BM‐MSCs and ASCs
with 0.5‐ and 0.6‐fold, respectively, both not significantly. The most obvi-
ous differences between BM‐MSCs and ASCs were therefore in ALP and
Col X expression patterns. This may indicate that ASCs are less commit-
ted to the osteogenic lineage compared with BM‐MSCs. More generally,
the response to osteogenic induction medium was highly similar in BM‐
MSCs and ASCs.3.4 | TECs made with BM‐MSCs are superior in bone
incidence and maturity
Previously we noted that ectopic bone formation by ASCs can be
induced by the addition of exogenous rhBMP2 to the culture medium
or TEC (Mehrkens et al., 2012). In another study, we showed that
aggregation stimulates ectopic bone formation by BM‐MSCS
(Chatterjea et al., 2013). To investigate whether the TEC strategy is
sufficient to drive ectopic bone formation, TECs with either BM‐
MSC‐ or ASC‐spheroids were implanted subcutaneously in immune‐
deficient mice. After 6 weeks the samples were analysed histologically
and scored for bone formation. TECs containing BM‐MSC spheroids
yielded bone in seven of 10 mice. Abundant mineralized matrix with
embedded osteocytes was observed. By contrast, no bone and no
spheroids were observed in ASC‐based TECs (Figure 4). We repeated
the experiments and included SVF spheroids and rhBMP2 as variables.
This time, three donors of ASCs and SVF (ASCs were derived from the
same donors as SVF) and one BM‐MSC donor were used. We used the
same donor of BM‐MSC as before as a constant factor between stud-
ies. The six conditions were: TECs with ASCs, TECs with BM‐MSC,
FIGURE 2 Spheroid formation seems to be cell source dependent. Cells were cultured for 24 h in multiwell agarose chips. In the overview images
of the microwells (left column), differences in condensation of the spheroids can clearly be seen. The enlargements show this in great detail (right
column) for one microwell. Large differences in condensation were seen in stromal vascular fraction (SVF) cells (compare donor 262 with 257 in the
first and second rows), which showed the least condensed spheroids if condensed at all. We observed improved spheroid formation in adipose‐
derived mesenchymal stromal cells (ASCs; third row) and superior condensation in bone marrow mesenchymal stromal cells (BM‐MSCs; fourth
row). The latter two being representative images of all spheroids. Scale bars indicate either 500 μm (left column) or 100 μm (right column)
e154 FENNEMA ET AL.TECs with SVF (with and without BMP2), no cells and no cells with
BMP2. The results are summarized in Table 1. Without cells, no bone
was observed (Figure 5A), indicating that neither fibrin gel nor the cal-
cium phosphate ceramics have sufficient osteoinductive features to
induce bone tissue formation. By contrast, the addition of rhBMP2
induced bone formation in 2/9 mice (Figure 5B, C). One SVF‐TECshowed bone formation (Figure 5D). TECs containing BM‐MSC spher-
oids displayed bone formation in 7/9 mice (Figure 5H, I). Interestingly,
this time bone formation was observed inTECs containing ASC aggre-
gates, although only in one of nine mice (Figure 5G shows an ASC‐TEC
without bone formation). Similarly, bone formation was observed in
SVF‐TECs in 1/9 mice, which increased to 4/9 mice when rhBMP2
FIGURE 3 Differentiation patterns differ between adipose‐derived (ASCs) and bone marrow mesenchymal stromal cells (BM‐MSCs) in induction
medium. Tissue engineered constructs (TECs) with ASCs and BM‐MSCs were cultured for 7 days in either basic or induction medium to simulate
implantation. Gene expression was related to the control (basic medium). For osteogenic differentiation, alkaline phosphatase (ALP), BMP2 and
collagen type I expression was measured: ALP was significantly upregulated in ASCs and BM‐MSCs (a), whereas BMP2 expression (b) was not
significantly different between conditions. The collagen type I expression (c) was significantly elevated in induced ASCs but not in BM‐MSCs. The
chondrogenic differentiation was analysed with collagen type II and collagen type X. Collagen type II was significantly upregulated in induced BM‐
MSCs only (d). The expression of collagen type X (e) was increased upon induction in BM‐MSCs, but decreased in ASCs. Vasculogenesis was
measured with VEGF expression, but did not differ between conditions (f)
FENNEMA ET AL. e155was included in the TEC (Figure 5E, F). Evaluation of the histological
slides further showed that BM‐MSC TECS showed the most mature
bone, followed by SVF + rhBMP2 and no cells + rhBMP2.4 | DISCUSSION
Bone graft substitutes are not yet commonplace in the treatment of
large bone defects. Several hurdles still hinder the adoption of this
treatment modality. One important factor is the number of autologous
stromal cells that can be harvested, because high numbers of cells are
generally required. Another factor is the ease of harvest. Readily avail-
able cell sources could catalyse their clinical use. The comparison of
stromal cells derived from adipose tissue vs. bone marrow is thereforemeaningful. Adipose tissue is indeed an easier source for stromal cells
than bone marrow. The exact yield per ml of adipose tissue vs. bone
marrow is hard to compare due to different yields of stromal cells in
the literature. For instance, the ratio in stromal cell yield of adipose tis-
sue/bone marrow can range from 7‐fold to 40‐fold (Bieback, Kern,
Kocaomer, Ferlik, & Bugert, 2008; Strem et al., 2005). On average,
yields of 1.5 × 105 SVF cells are typically obtained with the manual iso-
lation procedure, of which 10% are clonogenic ASC (Güven et al.,
2011). Despite these differences, adipose tissue is easier to obtain
and in larger quantities. Hence, it remains an attractive alternative to
bone marrow.
When using SVF cells directly to form spheroids, we noticed that
the spheroid formation was very different from donor to donor, unlike
ASCs and BM‐MSCs. BM‐MSCs and ASCs are less heterogeneous than
FIGURE 4 Bone marrow mesenchymal
stromal cells (BM‐MSCs) show bone formation
in vivo. To compare the bone‐forming capacity
of adipose‐derived mesenchymal stromal cells
(ASCs) and BM‐MSCs both were implanted in
NMRI‐nu mice. BM‐MSC‐based tissue
engineered constructs (TECs) showed mature
bone formation (a) indicated with a white
asterisk. ASC‐based TECs (b) only showed
fibrous tissue, indicated with a black asterisk.
Scaffolds are black in (a) and (b). In total 7/10
mice with BM‐MSC TECs showed bone
formation, compared with 0/10 in ASCs. All
samples in this study were embedded in
methyl methacrylate and stained with
methylene blue and basic fuchsin
FIGURE 5 Bone marrow mesenchymal stromal cells (BM‐MSCs) show more and more mature bone formation. The previous experiment was
repeated with the addition of more conditions to see if bone formation could be achieved with adipose‐derived mesenchymal stromal cells
(ASCs) and stromal vascular fraction (SVF). Six conditions were created: tissue engineered constructs (TECs) with ASCs, TECs with BM‐MSC, TECs
with SVF (with and without rhBMP2), no cells, no cells with rhBMP2. In TECs without cells we did not observe bone formation (a), only scaffolds
(black arrow). When rhBMP2 was added, bone formation (bright pink, asterisk) was seen in 2/9 mice (b). This was confirmed with Masson's
trichrome staining (c). SVF showed bone on one occasion, but usually no bone was seen (d). When rhBMP2 was added (e), bone formation was seen
in 4/9 mice (bright pink, asterisk) next to ceramic scaffolds (black arrow). Masson's trichrome staining (f) shows mature bone formation (asterisk)
next to scaffolds (black arrow). ASCs alone did not show any bone formation (g), only scaffolds (black arrow). BM‐MSC‐based TECs showed the
highest bone incidence (7/9) and the most mature bone (h, i; asterisks)
e156 FENNEMA ET AL.the source from which they are isolated as adherent cell fraction: red
bone marrow and SVF, respectively. The SVF contains cells of the
haematopoietic, vascular and mesenchymal lineages. Between studies,
the contribution of either of these populations in SVF varies (Bourinet al., 2013). We assume that this variation in cell types might interfere
with an efficient aggregation of SVF cells into spheroids. In a previous
study we have shown that spheroid formation significantly increases
osteogenic differentiation in vitro and bone formation in vivo (Chatterjea
FENNEMA ET AL. e157et al., 2013). Subsequently, we hypothesize that hampered spheroid
formation results in less (if any) bone formation that can probably only
be rescued by prolonged culturing and/or addition of rhBMP2.
Next to the hampered spheroid formation in vitro we observed
less bone formation in vivo in the SVF TECs (with or without the addi-
tion of rhBMP2). We can only speculate whether this is due to the lack
of spheroid formation or the relatively lower number of MSCs in the
SVF TECs, because the cell numbers are based on mononuclear cell
count. It is important to note, however. That this was the first time
ectopic bone formation by SVF cells was observed without any exten-
sive in vitro priming or addition of rhBMP2 (Mehrkens et al., 2012).
Furthermore, we observed more mature bone in TECs with BM‐
MSCs than with SVF + rhBMP2. The use of rhBMP2 in patients is
currently restricted to spinal fusion and tibial non‐union. Several
adverse events have been described following treatment with
rhBMP2, such as heterotopic ossification (Woo, 2013) and a higher
incidence of cancer (Cooper & Kou, 2013). Although these reports
should not be considered as causative analyses, a cell‐based
approach seems more favourable, even if the doses used in the pres-
ent study were much lower as compared with the surgically used,
rhBMP2‐based products.
We observed the highest bone incidence when using BM‐MSCs
and the bone formed also showed a higher degree of maturity as com-
pared with ASCs. This poses the question if this might be related to
their organ of origin. A common feature of MSC sources is that they
are situated in the vicinity of vascular structures (Putnam, 2014). Fur-
thermore, there is evidence suggesting that BM‐MSCs are more prone
to osteogenic differentiation than ASCs from the same donor (Im, Shin,
& Lee, 2005) and are programmed for skeletal development, as they
express RUNX3, RUNX2, BGLAP, MMP13 and ITGA10, whereas ASCs
do not (Reinisch et al., 2015). This ‘innate’ tendency for skeletal devel-
opment of BM‐MSCs might explain why they form bone more repro-
ducibly and also more mature bone than ASCs. Moreover, some
suggest that ASCs exhibit reduced chondrogenic capacity and
proangiogenic activity (Brocher et al., 2013). Our study compared
ASCs and BM‐MSCs and their capacity for osteogenic differentiation
in vitro and bone formation in vivo using spheroids without extensive
(chondrogenic or osteogenic) in vitro priming of implanted constructs.
We can confirm the lack of proangiogenic activity in vitro, as shown
by the absence of VEGF induction. This might be due to the
chondrogenic nature of the induction medium used (which is the same
as chondrogenic differentiation medium, but without the transforming
growth factor‐β), which should not stimulate vasculogenesis, as carti-
lage is avascular. After 1 week of in vitro culture with this induction
medium, Col II was significantly upregulated only in BM‐MSCs. This
is in line with the results of others that also showed that ASCs in
micromass culture show reduced chondrogenic differentiation capac-
ity in vitro and could only be induced by the addition of transforming
growth factor‐β and BMP6 (Hennig et al., 2007). As there was no anal-
ysis carried out on the origin of the bone, no claims can be made
regarding the contribution of host vs. donor cells and the differences
between ASCs and BM‐MSCs herein.
We conclude that aggregation can improve ectopic bone tissue
formation by adipose‐derived cells, but is less efficient than rhBMP2.
Furthermore, in this system, BM‐MSCs showed quantitatively andqualitatively superior ectopic bone formation without additional
growth factors. A combination of aggregated ASCs and rhBMP2
should now be tested to investigate a possible additive effect. In addi-
tion, a high throughput screening of small molecules to optimize aggre-
gation in ASCs might render rhBMP2 unnecessary.ACKNOWLEDGEMENTS
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